

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

Tamás Molnár

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A retrospective multicenter study of 391 ulcerative colitis patients found tofacitinib achieved steroid-free remission in 23.7% at 12 weeks and 41.1% at 52 weeks, with similar efficacy in acute severe and chronic active disease.

KEY POINTS

- Steroid-free remission rates were comparable between acute severe UC and chronic activity groups at both week 12 (26.0% vs 22.8%) and week 52 (34.2% vs 43.5%)
- Biologic-naïve patients achieved higher week 52 steroid-free remission compared to biologic-exposed patients (56.8% vs 38.7%, OR 2.078)
- Colectomy rates at week 52 were significantly higher in the acute severe UC group compared to chronic activity (17.6% vs 5.7%)
- Among 67 adverse events reported, 17.9% led to tofacitinib cessation and one thromboembolic event occurred
- The study enrolled patients between February and July 2022 with median follow-up of 26 weeks, categorizing indications as acute severe UC (27.1% of cohort) or chronic activity

VIEW THIS CONTENT ON GUTFLIX

<https://gutflifx.eu/search/d/0f7751b4-743c-11ee-927c-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.